Home Biosimilar Antibodies Immunology & Inflammation CD markers Oxelumab (Anti-TNFSF4 / OX40L / CD252)
For research use only. Not for use in humans.

Oxelumab (Anti-TNFSF4 / OX40L / CD252)

Synonyms: TNFSF4， OX-40L

Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa.

Oxelumab (Anti-TNFSF4 / OX40L / CD252)

Quality Control

Batch: A231401 Purity: 99% Protein concentration: 23.7mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa.

Product Details

CAS No. 1186098-83-8
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06812988 ACTIVE_NOT_RECRUITING Drug: Brivekimig|Drug: Placebo Type 1 Diabetes Mellitus Sanofi 2025-02-28 PHASE2
NCT04714983 SUSPENDED Liver Metastases; Liver Metastasis Colon Cancer; Colorectal Cancer; Breast Cancer; Gastric Cancer; Periampullary Cancer; Melanoma; Renal Cell Cancer; Sarcoma; Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors DNAtrix, Inc. 2021-02-15 PHASE1
NCT03739931 COMPLETED Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma; Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma ModernaTX, Inc. 2018-11-27 PHASE1
NCT05849922 COMPLETED Drug: SAR442970|Drug: Placebo Hidradenitis Suppurativa Sanofi 2023-06-06 PHASE2
NCT03894618 COMPLETED Drug: SL-279252 Squamous Cell Carcinoma of the Head and Neck; Melanoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Squamous Cell Carcinoma of the Anus; Squamous Cell Carcinoma of the Cervix; Squamous Cell Carcinoma of the Skin; Renal Cell Carcinoma; Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Mismatch Repair Deficient or MSI-High Solid Tumors Shattuck Labs, Inc. 2019-03-26 PHASE1
NCT05131477 COMPLETED Drug: Amlitelimab|Drug: Placebo Eczema; Atopic Dermatitis Kymab Limited 2021-12-13 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.